{
    "nct_id": "NCT05683457",
    "official_title": "A Phase 2, Observer-Blind, Placebo-Controlled Proof-of-Concept Trial to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus Vaccine in Patients Who Have Undergone Allogeneic Hematopoietic Cell Transplantation (HCT)",
    "inclusion_criteria": "* Receipt of an allogeneic HCT.\n* CMV-seropositive, defined as a documented positive test for anti-CMV IgG.\n* High-risk for CMV: HCT from related, unrelated, or haploidentical donor with post-transplant cyclophosphamide for graft-versus-host-disease (GVHD) prophylaxis; or HCT from related or unrelated donor with at least one mismatch at any of the following human leukocyte antigen (HLA) gene loci (HLA-A, B, C, and DRB1); or HCT from related or unrelated donor with myeloablative conditioning.\n* Persons of nonchildbearing potential or of childbearing potential with negative urine or serum pregnancy test on the day of first study injection.\n* Persons of childbearing potential who have practiced adequate contraception or have abstained from all activities that could result in pregnancy for at least 28 days prior to the first dose.\n* Persons of childbearing potential who have agreed to continue adequate contraception or abstain from all activities that could result in pregnancy through 3 months after last study injection.\n* Persons who are not currently breast/chestfeeding.\n* Willingness to comply with study procedures and provide written informed consent.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of a diagnosis or condition that, in the judgment of the Investigator, may affect participant safety, assessment of safety endpoints, assessment of immune response, or adherence to study procedures.\n* A documented positive human immunodeficiency virus (HIV) test.\n* Treatment with alemtuzumab (CampathÂ®), antithymocyte globulin (ATG), or any equivalent in-vivo T cell depleting agent within 12 months.\n* HCT with ex-vivo T cell depletion.\n* Low risk for CMV: HCT from related or unrelated donor with reduced intensity conditioning (RIC) and no other high-risk features.\n* History of prior hematopoietic cell transplantation within 12 months.\n* Receipt of prior investigational CMV vaccines or participation in another CMV therapeutic study that may interfere with study outcome measures as determined by the Investigator.\n* Suspected or known allergic reaction to any component of any mRNA vaccine or its excipients.",
    "miscellaneous_criteria": ""
}